



**GIG**  
CYMRU  
**NHS**  
WALES

Bwrdd Iechyd Prifysgol  
Bae Abertawe  
Swansea Bay University  
Health Board

Cadeirydd/Chair: **Emma Woollett**  
Prif Weithredwr/Chief Executive: **Mark Hackett**

**gofalu am ein gilydd, cydweithio, gwella bob amser**  
**caring for each other, working together, always improving**

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi.  
We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Dyddiad/Date: 27<sup>th</sup> September 2021  
Ein Cyf / Our Ref: 21-I-004

☎ 01639 648363

📧 FOIA.Requests@wales.nhs.uk  
Corporate Services  
Headquarters  
1 Talbot Gateway  
Baglan  
Port Talbot, SA12 7BR

[REDACTED]  
[REDACTED]

[REDACTED]

[REDACTED] of Information Act Request acknowledged by ourselves on 7<sup>th</sup> September 2021. Your request sought information relating to biologic medication.

Please note that we have provided this information for the period 01.06.21 to 31.08.21

**1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:**

- Abatacept [Orencia] 76 (please note that there is also some IV usage of this item within the Rheumatology day unit – patient numbers are not available for these issues)
- Adalimumab [Humira] 87
- Adalimumab Biosimilars 323
- Apremilast [Otezla] 30
- Baricitinib [Olumiant] 164
- Certolizumab [Cimzia] 45
- Etanercept [Enbrel] 111
- Etanercept Biosimilars 373
- Filgotinib [Jyseleca] 0
- Golimumab [Simponi] 27
- Guselkumab [Tremfya] 0
- Infliximab [Remicade] – this item is issued as stock to the Rheumatology day unit, therefore patient numbers are not available



**Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR**

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe  
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

- Infliximab Biosimilars – this item is issued as stock to the Rheumatology day unit, therefore patient numbers are not available
- Ixekizumab [Taltz] <5\*
- Risankizumab [Skyrizi] 0
- Rituximab [MabThera] <5\*
- Rituximab Biosimilars – this item is issued as stock to the Rheumatology day unit, therefore patient numbers are not available
- Sarilumab [Kevzara] 8
- Secukinumab [Cosentyx] 65
- Tocilizumab [Ro Actemra] 97 (please note that there is also some IV usage of this item within the Rheumatology day unit – patient numbers are not available for these issues)
- Tofacitinib [Xeljanz] 32
- Upadacitinib [Rinvoq] 19
- Ustekinumab [Stelara] 9

**2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs:**

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Secukinumab [Cosentyx]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]

Information to diagnosis level is not held on our Pharmacy systems. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

\* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and



its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2<sup>nd</sup> Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



Pam Wenger  
**Director of Corporate Governance**

